(All fields required)
Please enter a valid email.
Please enter your name.
Showing 11 - 16 of 16 records.
In this Phase I study, we will test the safety of the drug plerixafor (MOBOZIL) at different dose levels, used together with other anti-cancer drugs - cytarabine and etoposide. We want to find out what effects, good and/or bad, this combination of drugs has on leukemia. Plerixafor is a drug that bl...More
This randomized phase II/III trial is studying how well giving bortezomib and sorafenib tosylate together works in treating patients with newly diagnosed acute myeloid leukemia with or without mutations....More
This phase I trial studies the side effects and the best dose of crizotinib giving together with combination chemotherapy in treating younger patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. Crizotinib may stop the growth of tumor or cancer cells by blocking some...More
The main purpose of this study is to determine if sirolimus can be given safely in combination with standard drugs used to treat relapsed lymphoblastic leukemia/lymphoma....More
This phase I trial studies the side effects and
best dose of AR-42 when given together with decitabine in treating patients
with acute myeloid leukemia. AR-42 may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as decitabi...More
This partially randomized phase II trial studies
how well brentuximab vedotin or crizotinib and combination chemotherapy works
in treating patients with newly diagnosed stage II-IV anaplastic large cell
lymphoma. Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center